Plus   Neg

Dentsply Sirona Raises 2019 Guidance - Quick Facts

Dentsply Sirona Inc. (XRAY) said, in the second quarter, gross margin improved 130 basis points compared to prior year, and adjusted operating income margin expanded to over 20%. Based on the second-quarter financial performance, the company increased its adjusted EPS guidance for 2019.

For 2019, the company now expects adjusted earnings per share to $2.35 to $2.45, up from the previous range of $2.30 to $2.40. Reported revenue guidance range is estimated in a range of $3.95 to $4.05 billion. Internal sales growth is in the range of 4% to 5%. Analysts polled by Thomson Reuters expect the company to report profit per share of $2.36 on revenue of $4.03 billion. Analysts' estimates typically exclude special items.

For the second-quarter, non-US GAAP EPS was $0.66 compared to $0.60, prior year. On average, 16 analysts polled by Thomson Reuters expected the company to report profit per share of $0.63, for the quarter.

Second-quarter reported revenues were $1.01 billion, down 3.1% versus prior year and increased 3.0% on an internal sales growth basis. Analysts expected revenue of $1.04 billion for the quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
Follow RTT